BiotechTube

Pegvaliase

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonuria, Maternal

Conditions

Phenylketonuria, Maternal

Trial Timeline

Nov 22, 2022 → Oct 4, 2032

NCT ID
NCT05579548

About Pegvaliase

Pegvaliase is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonuria, Maternal. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05579548. Target conditions include Phenylketonuria, Maternal.

What happened to similar drugs?

7 of 20 similar drugs in Phenylketonuria, Maternal were approved

Approved (7) Terminated (1) Active (12)
❌SYNB1934v1 + PlaceboSynlogicPhase 3
🔄Kuvan®MerckPhase 3
✅Kuvan®MerckApproved
🔄Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
🔄BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
✅saproterin dihydrochlorideBioMarin PharmaceuticalApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (6)

NCT IDPhaseStatus
NCT06305234Pre-clinicalRecruiting
NCT05579548Pre-clinicalRecruiting
NCT05270837Phase 3Active
NCT05813678Pre-clinicalRecruiting
NCT03792451Pre-clinicalCompleted
NCT03694353Phase 3Completed

Competing Products

20 competing products in Phenylketonuria, Maternal

See all competitors
ProductCompanyStageHype Score
mRNA-3210ModernaPhase 2
0
SYNB1934v1 + PlaceboSynlogicPhase 3
22
SYNB1618 + PlaceboSynlogicPhase 1/2
22
SYNB1618 + SYNB1934SynlogicPhase 2
25
Kuvan®MerckPhase 3
40
Kuvan®MerckApproved
43
SAR444836SanofiPhase 1/2
36
KuvanBioMarin PharmaceuticalPre-clinical
15
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
rAvPAL-PEGBioMarin PharmaceuticalPhase 2
32
Sapropterin (Kuvan)BioMarin PharmaceuticalPre-clinical
23
BMN 165 (rAvPAL-PEG)BioMarin PharmaceuticalPhase 2
32
BMN 307BioMarin PharmaceuticalPhase 1/2
33
SapropterinBioMarin PharmaceuticalPre-clinical
23
Sapropterin dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37
BMN165 20mg/day + BMN165 40mg/day + PlaceboBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
saproterin dihydrochlorideBioMarin PharmaceuticalApproved
40
sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placeboBioMarin PharmaceuticalPhase 1
26
PegvaliaseBioMarin PharmaceuticalPre-clinical
30